LUNA rises by 2.66% despite ongoing legal uncertainties and unstable market conditions

On November 15, 2025, LUNA experienced a 2.66% increase over the past day, reaching $0.081. This uptick comes after the token suffered losses of 11.76% over the previous week and 13.28% in the last month. Despite the recent rebound, LUNA remains far below its yearly high, having dropped 80.47% in value over the past twelve months.

Legal pressures are mounting for those who have invested in

, a company trading under the symbol . The law firm Faruqi & Faruqi has issued a notice to investors who may wish to serve as lead plaintiffs in an ongoing class-action case. The lawsuit alleges that misleading information was provided between March 10, 2024, and September 29, 2025, especially regarding the scientific differences between nanobodies and monoclonal antibodies. Investors impacted by these claims are encouraged to reach out to the firm before the December 15 deadline for lead plaintiff applications.

The core of the complaint is that MoonLake’s management exaggerated the clinical benefits of its drug candidate SLK compared to BIMZELX, a monoclonal antibody from another company. The suit claims that MoonLake did not reveal that SLK’s nanobody design offered no significant clinical improvement over existing therapies. It also alleges that the purported tissue-penetration benefits of nanobodies failed to deliver real-world efficacy for patients. Investors are advised to consider their legal choices as the company continues to analyze data from its Phase 3 VELA study, which was made public in early September 2025.

Analysis of MoonLake’s stock and related securities indicates that disappointing earnings do not always result in immediate declines. A review of trading patterns following earnings misses from 2022 to 2025 shows varied market reactions. In four instances, the stock showed upward momentum in the first three trading days after the announcement, averaging a 2.65% gain above the market. This suggests that traders may benefit from short-term rallies or buying on dips. However, these gains tend to fade, with returns turning negative between days 9 and 20, before partially rebounding by the 30th day.

Backtest Hypothesis

The backtest explored how MLTX performed after reporting earnings below expectations. Findings indicate a potential advantage in buying the stock within three days of a negative earnings report and selling soon after, capturing small positive returns. Prolonged holding beyond a week led to greater price swings and reduced chances of profit. The strategy’s success rate dropped sharply after the first week, with only about a quarter of trades remaining profitable between days 9 and 24. These results imply that while there are short-term opportunities, holding for longer periods increases risk.